Krosyl Pharmaceuticals Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Krosyl Pharmaceuticals Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $600.0K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Krosyl Pharmaceuticals Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $600.0K Trade | TransData Nexus

Krosyl Pharmaceuticals Private Limited

Indian Pharmaceutical Exporter · Antimalarial & Antiparasitic Specialist · $600.0K Total Trade · DGFT Verified

Krosyl Pharmaceuticals Private Limited is an Indian pharmaceutical exporter with a total trade value of $600.0K across 4 products in 3 therapeutic categories. Based on 12 verified export shipments from Indian Customs (DGFT) records, Krosyl Pharmaceuticals Private Limited is the #1 Indian exporter in 1 product including Mebendazole. Top exports include Albendazole ($150.0K), Flucloxacillin ($150.0K), Fluconazole ($150.0K).

Krosyl Pharmaceuticals Private Limited — Export Portfolio & Destination Treemap

Krosyl Pharmaceuticals Private Limited pharmaceutical export portfolio — 4 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Krosyl Pharmaceuticals Private Limited? — Company Overview & Market Position

Krosyl Pharmaceuticals Private Limited, established on January 5, 2015, is a privately held pharmaceutical company headquartered in Vadodara, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U24100GJ2015PTC081717. With an authorized and paid-up capital of ₹5 million, Krosyl Pharmaceuticals operates in the manufacturing sector, focusing on the production of pharmaceutical finished formulations.

The company's mission is to become a global healthcare organization recognized for its integrated healthcare and pharmaceutical solutions through innovation, quality, and competence. Krosyl Pharmaceuticals aims to provide high-quality, affordable medicines to support patients in need, striving to improve access and affordability, create healthier communities, and promote a healthy mind, body, and environment worldwide.

What Does Krosyl Pharmaceuticals Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Albendazole$150.0K 2

Product Portfolio — Top 4 by Export Value

Krosyl Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Albendazole	Antimalarial & Antiparasitic	$150.0K	3	0.2%	9
2	Flucloxacillin	Advanced Antibiotics	$150.0K	3	0.4%	3
3	Fluconazole	Antifungals	$150.0K	3	0.2%	12
4	Mebendazole	Antimalarial & Antiparasitic	$150.0K	3	1.1%	1

Krosyl Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories with a total export value of $600.0K. The company is the #1 Indian exporter in 1 product: Mebendazole. The top category is Antimalarial & Antiparasitic (50.0% of portfolio), followed by Advanced Antibiotics (25.0%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Krosyl Pharmaceuticals Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Krosyl Pharmaceuticals operates manufacturing facilities in Vadodara, Gujarat, India. The company emphasizes maintaining high-quality standards in its manufacturing processes, adhering to Good Manufacturing Practice (GMP) guidelines. Krosyl Pharmaceuticals is certified by the World Health Organization (WHO) for GMP compliance, ISO 9001:2008, and Good Laboratory Practice (GLP), ensuring the production of safe and effective pharmaceutical products.

3Key Leadership

The leadership team at Krosyl Pharmaceuticals includes:

Parth Joshi: Founder and CEO, leading the company's strategic direction and operations.

Amit Prabhudas Patel: Director, appointed on July 30, 2024, contributing to the company's governance and strategic initiatives.

Nilesh Prajapati: Director, serving since the company's inception on January 5, 2015, providing leadership and oversight.

Parth Rameshkumar Joshi: Director, also serving since January 5, 2015, involved in the company's strategic decision-making processes.

Maulik R Joshi: Director, appointed on July 30, 2024, playing a role in the company's strategic planning and execution.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Krosyl Pharmaceuticals Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Krosyl Pharmaceuticals has established a presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained certifications such as WHO-GMP and ISO 9001:2008, which are recognized by regulatory authorities in these regions. These certifications facilitate market access and demonstrate the company's commitment to maintaining high-quality manufacturing standards.

2Emerging Markets

Krosyl Pharmaceuticals has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO-GMP certification enhances its ability to meet international quality standards, facilitating access to these markets. By offering affordable and high-quality pharmaceutical products, Krosyl Pharmaceuticals aims to address the healthcare needs of diverse populations in these regions.

3Geographic Strategy

Krosyl Pharmaceuticals' geographic strategy involves a balanced approach, focusing on both established and emerging markets. The company's WHO-GMP and ISO 9001:2008 certifications support its expansion efforts, enabling it to navigate regulatory requirements effectively. By diversifying its market presence, Krosyl Pharmaceuticals mitigates concentration risks and positions itself for sustainable growth in the global pharmaceutical industry.

Krosyl Pharmaceuticals Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, specific details regarding Krosyl Pharmaceuticals' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's focus on maintaining WHO-GMP and ISO 9001:2008 certifications indicates a commitment to quality standards recognized by international regulatory bodies.

2WHO & EU GMP

Krosyl Pharmaceuticals holds WHO-GMP certification, demonstrating compliance with international manufacturing standards. This certification is recognized by the European Union, facilitating market access within EU member states. The company's adherence to these standards underscores its commitment to producing high-quality pharmaceutical products.

3CDSCO & Indian Regulatory

Krosyl Pharmaceuticals operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's WHO-GMP and ISO 9001:2008 certifications align with CDSCO's requirements for pharmaceutical manufacturing. These certifications reflect the company's adherence to national and international quality standards, ensuring the safety and efficacy of its products.

Krosyl Pharmaceuticals Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Krosyl Pharmaceuticals operates in a competitive landscape, with several companies offering similar pharmaceutical products. While specific market share data is not publicly available, the company's WHO-GMP and ISO 9001:2008 certifications position it favorably in the market. These certifications enhance the company's credibility and appeal to customers seeking high-quality pharmaceutical products.

2Key Differentiators

Krosyl Pharmaceuticals differentiates itself through its commitment to innovation, quality, and affordability. The company's WHO-GMP and ISO 9001:2008 certifications reflect its adherence to international manufacturing standards. By focusing on providing high-quality pharmaceutical products at affordable prices, Krosyl Pharmaceuticals aims to build a healthier world for people.

3Strategic Position

Krosyl Pharmaceuticals' strategic direction centers on becoming a global healthcare organization recognized for its integrated pharmaceutical solutions. The company's focus on innovation, quality, and competence supports its mission to provide high-quality, affordable medicines. By maintaining WHO-GMP and ISO 9001:2008 certifications, Krosyl Pharmaceuticals demonstrates its commitment to meeting international standards and addressing diverse medical needs.

Buyer Due Diligence Brief — Evaluating Krosyl Pharmaceuticals Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Krosyl Pharmaceuticals maintains a strong track record in pharmaceutical manufacturing, as evidenced by its WHO-GMP and ISO 9001:2008 certifications. The company's commitment to quality and compliance with international standards indicates reliability in its manufacturing processes. While specific export volumes and consistency data are not publicly available, the company's certifications suggest a focus on delivering high-quality products to its customers.

2Certifications to Verify

Importers should verify the following certifications when considering Krosyl Pharmaceuticals as a supplier:

WHO-GMP Certification: Indicates compliance with international manufacturing standards. Verification can be done through the World Health Organization's official channels.

ISO 9001:2008 Certification: Demonstrates adherence to quality management systems. Verification can be conducted through the International Organization for Standardization's official website.

Due Diligence Checklist

Frequently Asked Questions — Krosyl Pharmaceuticals Private Limited

How many pharmaceutical products does Krosyl Pharmaceuticals Private Limited export from India?

Krosyl Pharmaceuticals Private Limited exports 4 pharmaceutical products across 3 therapeutic categories. The top exports are Albendazole ($150.0K), Flucloxacillin ($150.0K), Fluconazole ($150.0K), Mebendazole ($150.0K). Total export value is $600.0K.

What is Krosyl Pharmaceuticals Private Limited's total pharmaceutical export value?

Krosyl Pharmaceuticals Private Limited's total pharmaceutical export value is $600.0K, based on 12 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Krosyl Pharmaceuticals Private Limited the #1 Indian exporter?

Krosyl Pharmaceuticals Private Limited is the #1 Indian exporter in 1 products: Mebendazole (1.1% market share).

What therapeutic categories does Krosyl Pharmaceuticals Private Limited cover?

Krosyl Pharmaceuticals Private Limited exports across 3 therapeutic categories. The largest are Antimalarial & Antiparasitic (50.0%, 2 products), Advanced Antibiotics (25.0%, 1 products), Antifungals (25.0%, 1 products).

Get Full Krosyl Pharmaceuticals Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.